Literature DB >> 17652294

Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.

Barry J Maron1, Paolo Spirito, Win-Kuang Shen, Tammy S Haas, Francesco Formisano, Mark S Link, Andrew E Epstein, Adrian K Almquist, James P Daubert, Thorsten Lawrenz, Giuseppe Boriani, N A Mark Estes, Stefano Favale, Marco Piccininno, Stephen L Winters, Massimo Santini, Sandro Betocchi, Fernando Arribas, Mark V Sherrid, Gianfranco Buja, Christopher Semsarian, Paolo Bruzzi.   

Abstract

CONTEXT: Recently, the implantable cardioverter-defibrillator (ICD) has been promoted for prevention of sudden death in hypertrophic cardiomyopathy (HCM). However, the effectiveness and appropriate selection of patients for this therapy is incompletely resolved.
OBJECTIVE: To study the relationship between clinical risk profile and incidence and efficacy of ICD intervention in HCM. DESIGN, SETTING, AND PATIENTS: Multicenter registry study of ICDs implanted between 1986 and 2003 in 506 unrelated patients with HCM. Patients were judged to be at high risk for sudden death; had received ICDs; underwent evaluation at 42 referral and nonreferral institutions in the United States, Europe, and Australia; and had a mean follow-up of 3.7 (SD, 2.8) years. Measured risk factors for sudden death included family history of sudden death, massive left ventricular hypertrophy, nonsustained ventricular tachycardia on Holter monitoring, and unexplained prior syncope. MAIN OUTCOME MEASURE: Appropriate ICD intervention terminating ventricular tachycardia or fibrillation.
RESULTS: The 506 patients were predominately young (mean age, 42 [SD, 17] years) at implantation, and most (439 [87%]) had no or only mildly limiting symptoms. ICD interventions appropriately terminated ventricular tachycardia/fibrillation in 103 patients (20%). Intervention rates were 10.6% per year for secondary prevention after cardiac arrest (5-year cumulative probability, 39% [SD, 5%]), and 3.6% per year for primary prevention (5-year probability, 17% [SD, 2%]). Time to first appropriate discharge was up to 10 years, with a 27% (SD, 7%) probability 5 years or more after implantation. For primary prevention, 18 of the 51 patients with appropriate ICD interventions (35%) had undergone implantation for only a single risk factor; likelihood of appropriate discharge was similar in patients with 1, 2, or 3 or more risk markers (3.83, 2.65, and 4.82 per 100 person-years, respectively; P = .77). The single sudden death due to an arrhythmia (in the absence of advanced heart failure) resulted from ICD malfunction. ICD complications included inappropriate shocks in 136 patients (27%).
CONCLUSIONS: In a high-risk HCM cohort, ICD interventions for life-threatening ventricular tachyarrhythmias were frequent and highly effective in restoring normal rhythm. An important proportion of ICD discharges occurred in primary prevention patients who had undergone implantation for a single risk factor. Therefore, a single marker of high risk for sudden death may be sufficient to justify consideration for prophylactic defibrillator implantation in selected patients with HCM.

Entities:  

Mesh:

Year:  2007        PMID: 17652294     DOI: 10.1001/jama.298.4.405

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  125 in total

1.  Heart disease and stroke statistics--2012 update: a report from the American Heart Association.

Authors:  Véronique L Roger; Alan S Go; Donald M Lloyd-Jones; Emelia J Benjamin; Jarett D Berry; William B Borden; Dawn M Bravata; Shifan Dai; Earl S Ford; Caroline S Fox; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Diane M Makuc; Gregory M Marcus; Ariane Marelli; David B Matchar; Claudia S Moy; Dariush Mozaffarian; Michael E Mussolino; Graham Nichol; Nina P Paynter; Elsayed Z Soliman; Paul D Sorlie; Nona Sotoodehnia; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner
Journal:  Circulation       Date:  2011-12-15       Impact factor: 29.690

2.  Economic evaluation of strategies to reduce sudden cardiac death in young athletes.

Authors:  Michael Schoenbaum; Peter Denchev; Benedetto Vitiello; Jonathan R Kaltman
Journal:  Pediatrics       Date:  2012-07-02       Impact factor: 7.124

Review 3.  Role of animal models in HCM research.

Authors:  Rhian Shephard; Christopher Semsarian
Journal:  J Cardiovasc Transl Res       Date:  2009-08-07       Impact factor: 4.132

4.  Device therapy: a subcutaneous ICD--preliminary results.

Authors:  Paolo Spirito; Giuseppe Boriani
Journal:  Nat Rev Cardiol       Date:  2010-10       Impact factor: 32.419

Review 5.  Hypertrophic cardiomyopathy in childhood.

Authors:  Steven D Colan
Journal:  Heart Fail Clin       Date:  2010-10       Impact factor: 3.179

Review 6.  Hypertrophic cardiomyopathy: from genetics to treatment.

Authors:  Ali J Marian
Journal:  Eur J Clin Invest       Date:  2010-04       Impact factor: 4.686

7.  [The ICD as primary prevention. Rare indications].

Authors:  K Wasmer; J Köbe; C Pott; L Eckardt
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2010-06

8.  Primary prevention with the ICD in clinical practice: not as straightforward as the guidelines suggest?

Authors:  F A L E Bracke; L R C Dekker; P H van der Voort; A Meijer
Journal:  Neth Heart J       Date:  2009-03       Impact factor: 2.380

9.  High signal intensity on T2-weighted cardiac magnetic resonance imaging correlates with the ventricular tachyarrhythmia in hypertrophic cardiomyopathy.

Authors:  Yasuki Hen; Nobuo Iguchi; Haruhiko Machida; Kaori Takada; Yuko Utanohara; Tetsuya Sumiyoshi
Journal:  Heart Vessels       Date:  2012-10-25       Impact factor: 2.037

10.  Therapeutic options in hypertrophic cardiomyopathy: a pediatric perspective.

Authors:  Edward K Rhee; John J Nigro; Stephen G Pophal
Journal:  Curr Treat Options Cardiovasc Med       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.